subject: Pre-treated Metastatic Christian Louboutin [print this page] "In a case-series report carried out in both anthracycline-naive and pre-treated metastatic breast cancer patients, we tested feasibility, clinical efficacy and tolerability of PLD administered with a novel metronomic schedule of 20mg/m[superscript]2 i.v. every two weeks. christian louboutin52 patients were enrolled and 45 were evaluated. Forty-four patients were assessed for either response or toxicity. Eight patients (18%) had partial responses (PR) and 17 (39%) stable disease (SD), with a clinical benefit (CB) of 45% (95% CI: 30.3%-59.7%). Nineteen patients (43%) had progressive disease (PD). Neither grade 3 nor grade 4 haematological or clinical side effects were recorded, except for 2 patients with grade 3 palmar-plantar erythrodysesthesia (PPE). No cardiac toxicity was recorded," wrote E. Munzone and colleagues, European Institute of Oncology, Division of Medical Oncology. Louboutin Shoes sale
The researchers concluded: "Metronomic administration of PLD is a feasible and active treatment for extensively pre-treated metastatic breast cancer patients, alternative to classic anthracyclines, balancing clinical efficacy with a good quality of life in terms of reduced side effects and low personal costs for the patient." Louboutin Pumps
Munzone and colleagues published their study in Breast (Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report. Breast, 2010;19(1):33-7).
For additional information, contact E. Munzone, European Institute of Oncology, Division of Medical Oncology, via Ripamonti 435, Milan, Italy. Louboutin Boots
